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Thrombomodulin is synthesized by human mesangial cells
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Thrombomodulin is synthesized by mesangial cells. Thrombomodulin
(TM), an endothelial receptor for thrombin, endowed with a powerful
anticoagulant activity, plays an important role in the antithrombogenicity
of the vascular endothclium. Its presence within the human renal glomer-
ulus is already known hut was thought to he only endothelial. We looked
for TM expression in human mesangial cells (MC), both in situ, in freshly
prepared glomeruli, and in primary culture. Both fresh and cultured MC
were strongly reactive for TM by immunocytochemical methods. Total
TM antigen measured on MC lysates and surface TM activity on MC were
0.292 0.075 ng/mg of cellular proteins and 1.20 0.02 pmole of
activated protein C/mm/mg of cellular proteins, respectively. As shown by
the presence of numerous transcripts detected by in situ hybridization, TM
was shown to he synthesized by MC in vivo and in culture. The synthesis
of active TM by both endothelial and mesangial cells within the renal
glomerulus stresses the importance of its role in maintaining renal
hemostatic equilibrium, and sheds some light on the conflicting reports of
TM over- and underexpression in glomerulopathies to open a new field for
investigation.
Thrombomodulin (TM) is an antithrombotic proteoglycan
[1—4] present on the vascular surface of endothelial cells and is a
receptor for thrombin. Once bound to TM, thrombin activates
protein C (PC), thereby engaging its powerful anticoagulant
pathway [5]. Simultaneously, thrombin loses its procoagulant
capacities vis-à-vis its substrates, fibrinogen and factor V [6], and
is no longer able to aggregate platelets [7]. The chondroitin
sulfate moiety of TM displays also a heparin-like activity in the
presence of antithromhin III [8].
Renal mesangial cells (MC) are known to respond to several
vasoactive substances including thrombin, which has been shown
to induce their constriction and proliferation, variations of their
shape and their adhesion to different surfaces in culture [9—11].
Thrombin can be considered as a mitogenic agent, like arginine-
vasopressin or insulin-like growth factor-I [12], and is also in-
volved in the regulation of the fibrinolytic system in the human
glomerulus [13].
MC proliferation, expansion of the extracellular matrix and
fibrin formation in the glomerular urine space arc the hallmarks
of so-called proliferative glomerulonephritis [14]. These phenom-
ena arc in part responsible for the ischcmic injury of renal tubules
and interstitium. They might initiate sclerotic processes through
the stimulation of transforming growth factor-p and platelet-
derived growth factor [15, 161. However, under normal steady-
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state conditions, these harmful events do not occur owing to
preventive counteracting systems. The thrombin-TM complex is
considered to be one of these, and heparin and heparan sulfates
have recently been shown to inhibit renal MC mitogenesis [17]. In
1992, He and Kanfer [18] showed that detergent extracts of rat
glomeruli displayed TM activity, which was down-regulated by
tumor necrosis factor-a and lipopolysaccharide, and that human
glomeruli contained TM antigen. They used total glomerular
extracts that did not allow the determination of the cell type
responsible for the TM activity detected.
Indeed, glomerular endothelial cells, like endothelial cells from
any vascular bed, express TM. Our findings, reported herein,
demonstrate that TM is expressed by MC in freshly prepared
glomeruli and by MC in culture. Moreover, the presence cf
TM-mRNA shown by in situ hybridization confirmed that TM is
synthesized in vivo.
Methods
Preparation of MC from freshly treated human glomeruli
Human renal cortex was obtained, with patients' informed
consent, from the normal pole of eight whole kidneys removed
because of a cancerous indication. The samples were taken
immediately after the renal blood vessels had been clamped and
were processed within 15 minutes for glomerulus preparation.
Glomeruli were isolated according to a previously described
procedure [13, 19] with minor modifications. The renal cortex was
forced through a 180-mm-pore stainless steel sieve to dissociate
tubules and Bowman's capsule from other glomerular structures.
These latter were thereafter collected on a 60-mm-pore stainless
steel sieve and digested by 0.2% collagenase H (Boehringer,
Mannheim, Germany) for 30 minutes at 37°C. The collagenase-
treated glomeruli were then collected on a 60-mm-pore sieve,
washed in phosphate-buffered saline (PBS) and one aliquot was
immediately cytocentrifuged on gelatin-coated slides (800 rpm for
4 mm in a Shandon cytospin centrifuge) for immunocytochemistry
and in situ hybridization. They were fixed in 4% paraformalde-
hyde (PFA), pH 7.4, for 10 minutes, washed in PBS, dried at 37°C
and immediately processed or stored at —80°C.
MC primary culture
The other aliquot of collagenase treated glomeruli was plated
on rat type I collagen (Boehringer)-coated dishes for MC culture,
in Waymouth medium supplemented with 20% heat-inactivated
fetal calf serum (FCS), 5 mg/mI of insulin, 5 mg/mI of transferrin,
1% non-essential amino acid solution and 2% pyruvate. MC
appeared within 10 days (primary culture). Confluent MC were
maintained in Waymouth medium containing 2% FCS for 24
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Table 1. Antibodies used for immunocytochemical analyses
IgG to human Origin Dilution
-
Secondary antibody° Dilution Method Positive control cells'1
Rabbit F(ab')2 anti-sheep IgG(H+L) ABC HUVEC
Goat IgG anti-rabbit lgG 2-step HUVEC
Rabbit IgG anti-mouse IgG ABC HASMC
Rabbit TgG anti-mouse IgG ABC Podocyte
Abbreviations are: TM, thrombomodulin; vWF, von Willebrand factor; SM, smooth muscle; HUVEC, human umbilical vein endothelial cell;
HASMC, human aortic smooth muscle cell; HSF, human skin fibroblast; ND, not done.
° Polyclonal antiserumh Monoclonal antibody (1A4)
C From Dakopatts
'1Negative control cells for all antibodies were human skin fibroblasts
Table 2. Immunoreactivity of freshly isolated and cultured mesangial
cells
Antibody to
Fresh
MC
Cultured
MC
Control cells
HUVEC HASMC Podocytes HSF
TM + + + ND ND -
vWF — — + — ND —
Podocalyxin — — ND ND + —
SM a-actin — + ND
Negative controls were obtained using preimmune sera for TM and
non-immune sera for the other antigens. Symbols are: +, present;
absent. Abbreviations are: TM, thrombomodulin; vWF, von Willebrand
factor; SM, smooth muscle; HUVEC, human umbilical vein endothelial
cell; HASMC, human aortic smooth muscle cell; HSF, human skin
fibroblast; ND, not done.
hours prior to each experiment performed with three different
kidneys. MC were dissociated by trypsin-ethylenediaminetet-
raacetic acid (EDTA) solution, plated on gelatin-coated slides for
immunocytochemistry and in situ hybridization analyses and im-
mediately fixed as described above.
Control cells
For immunocytochemistry and in situ hybridization studies,
different kinds of cells cultured in our laboratory were processed
concurrently: HUVEC [20], human skin fibroblasts and human
aortic smooth muscle cells isolated according to the explant
technique [21] and human cultured podocytes [22].
Immunocytochemical analysis
MC in colfagenase-treated glomcruli and in ccli cultures were
characterized by imniunocytochemistry. To ascertain the absencc
of endothelial cells and podocytes, vWF and podocalyxin [23]
were examined. An antibody to smooth muscle s-actin was also
applied to characterize MC in culture (24, 25].
The slides were permeabilized as follows: for smooth muscle,
a-actin with 0.1% Triton X-l00 for five minutes, followed by cold
acetone at —20°C for two minutes; for vWF, with 200 U trypsin/mi
of PBS for 10 minutes. After inhibition of endogenous peroxidase
as described by Heyderman [26], the nonspecific adsorption of
antibodies was blocked with 0.2% bovine serum albumin (BSA) in
PBS. The slides were then incubated with the unlabeled primary
antibody overnight at 4°C. Depending on the antigen, prepara-
tions were thereafter processed using either the avidin-biotin
complex immunoperoxidase method (ABC Vectastain kit; Vector,
Burlingame, CA, USA) described by Hsu, Raine and Fanger [27],
or the two-step indirect method (Table 1). All antisera, whose
origins and dilutions are given in Table 1, were diluted in PBS
containing 0.1% BSA. The peroxidase activity was visualized with
the chromogen aminoethylcarbazol (peroxidase substrate kit
AEC; Vector). After counterstaining with methyl green, slides
were mounted in glycerin jelly and coverslipped. Two kinds of
controls were used: (1) the primary antibody was replaced by
preimmune immunoglobulins for TM, or by non-immune sera for
the other antigens; and (2) two kinds of cells were processed with
immune sera, one known to contain the test antigen (positive
control) and the other not (negative control; Table 1).
TM antigen and activity
TM antigen was determined in a detergent extract of fresh MC
(approximately 500 fresh collagenase-treated glomeruli) or of
cultured MC (6 culture wells) suspended in 25 1.d of PBS
containing 1% Triton X-100, 5 m N-ethyl maleimide and 2 mivi
phenylmethylsulfonyl fluoride. After solubilization, the lysate was
centrifuged (12,000 rpm for 5 mm at 4°C). TM antigen in the clear
supernatant was measured using Asserachrom TM ELISA [28],
provided by Diagnostica Stago. Total cell protein content of the
same extract was measured using the BCA protein reagent from
Pierce (Rockford, IL, USA).
Surface TM activity was evidenced on fresh MC from approx-
imately 500 glomeruli and was quantified on confluent primary
MC monolayers. It was measured as the cofactor of PC activation
using a chromogenic assay described by Archipoff et al [29] with
CBS 4246 as chromogenic substrate. The amount of aPC gener-
ated was determined using a standard curve obtained from known
concentrations of purified aPC. All reagents were from Diagnos-
tica Stago (Asnières, France).
lit situ hybridization
ISH was performed in view to investigate TM synthesis in MC,
in vitro and cx vivo in freshly isolated MC. Since these latter MC
were fixed within a maximum of 90 minutes after kidney removal,
ISH allowed their initial in vivo mRNA status to be studied, in
spite of some possible mRNA degradation.
TM probe. The 650-bp fragment of the human TM eDNA
cloned into pGem 4 plasmid was a gift from R.W. Jackman (Beth
Israel Hospital, Harvard Medical School, Boston, MA, USA). The
antisense and sense probes were obtained, respectively after
linearization of the plasmid with EcoRl and KonI (Promega,
Madison, WI, USA). Two S (35S-UTP; Amersham, Les Ulis,
France)-laheled RNA probes were synthesized using SP6 and T7
polymerases (Promega) and according to the transcription-kit
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Fig. 1. Absence of contamination of MC freshly isolated from human glomeruli by endothelial cells and podocytes. Cytocentrifuged collagenase-treated
glomeruli were analyzed by immunocytochemistry. No reaction was observed using antibodies against vWF (A) and podocalyxin (B) (X500).
Fig. 2. TM expression in fresh MC studied by immunoperoxidase staining. Strong positive reaction showing a diffuse granular pattern (A) and absence of
reaction (B) when using anti-TM antibodies and preimmune serum, respectively (X1000).
manufacturer's recommendations (Riboprobe Core System tran-
scription kit; Promega).
In situ hybridization procedure. The method published by Hofler
et at [30] was used. Briefly, after washing with PBS, fixed slides
were incubated successively in PFA, glycine, Triton X-100, pro-
teinase K. Slides were then acetylated, prehybridized in 4 X
saline-sodium citrate (SSC):formamide (1:1) for one hour at 42°C.
Hybridization was done overnight at 42°C, in 10 jl of buffer
containing 1.2 x 106 cpm of 35S-UTP-labeled probe. The slides
were then washed at 37°C with decreasing SSC concentrations and
RNase A digestion was carried out. Then slides were dehydrated,
air-dried, dipped into LM-1 autohistoradiographic emulsion (Am-
ersham) and, after six days at 4°C, developed in Kodak D19. After
counterstaining with methyl green, they were dehydrated, resin-
mounted and coverslipped. Negative controls included cells pre-
treated with RNase A before hybridization and the use of a sense
probe. Moreover, HUVEC and human skin fibroblasts processed
with the antisense probe, were used, respectively, as positive and
negative controls.
Results
TM expression in MC from freshly treated human kidney
MC appeared as cell clusters surrounded by an abundant
matrix. The MC preparations were free of endothelial material
and podocytes, as evidenced by negative immunolabeling for von
Willebrand factor (vWF) (Fig. IA) and podocalyxin (Fig. IB).
Despite collagenase treatment, a podocyte contamination was
sometimes observed in glomeruli prepared from older patients
and these contaminated samples were discarded. Only rare MC
expressed smooth muscle a-aetin (data not shown), as it was
expected in samples obtained from uninjured kidneys [24]. MC
showed a strong reactivity to TM and stained with diffuse granular
pattern (Fig. 2A). No staining was observed in slides treated with
preimmune immunoglobulins (Fig. 2B). As regards control cells,
HUVEC expressed strong TM positivity whereas human skin
fibroblasts were negative (data not shown).
TM expression in cultured MC
Under the phase contrast microscope, confluent MC in primary
culture were elongated (Fig. 3A) and there was no evidence for
the presence of either glomerular endothelial or epithelial cells.
Primary cultures homogeneously and strongly expressed smooth
muscle cE-actin (Fig. 3B) and were devoid of vWF (Fig. 3C) and of
podocalyxin (Fig. 3 D). As for native MC, strong TM reactivity
was observed in cultured MC (Fig. 4A) which remained unstained
in the presence of preimmune immunoglobulins (Fig. 4B). Results
of the immunocytochemical study are summarized in Table 2.
TM antigen and surface TM activity
Total TM antigen was constantly found in lysed fresh MC and
TM activity was present at the surface of these MC. However,
these parameters could not be quantified in freshly isolated MC
because of the presence of an abundant extraccllular matrix,
which interferes in the calculations, falsely increasing the protein
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Fig. 3. Characterization of MC in pri'naty cultures. Phase Contrast microscopy showing the morphology of MC before trypsinization. (A) Explanted
glomeruli gave rise to elongated spindle-shaped cells which formed multilayers after confluence (X100). Immunocytochemistry (B.D). Cultured cells
expressed smooth muscle a-aeOn (B) and were negative either for vWF (C) or podocalyxin (D) (X500).
Fig. 4. TM expression in cultured MC. Typical immunostaining of cultured MC with most of the cells heavily stained (A) and absence of reaction (B)
when using anti-TM antibodies and pre-inimune serum, respectively (X500).
level of the sample and thus underestimating TM expression.
Total TM antigen and surface activity values in MC in primary
culture were: 0.292 0.075 ng/mg of cellular proteins and 1.20
0.02 pmole of activated PC (aPC)/minlmg of cellular proteins,
respectively.
Detection of TM rnRNA in MC
In situ hybridization showed the presence of TM transcripts in
MC. They were as abundant in freshly prepared (Fig. 5A) as in
cultured MC (Fig. 5B). The sense probe gave no specific signal in
either one (Fig. 5 C, D). In control cells, strong signals of TM
mRNA expression were observed in HUVEC (Fig. SE) whereas
no silver grains were seen on human skin flbrohlasts (Fig. 5F). No
hybridization with the antisense probe was observed in RNase
A-pretreated cells (result not shown).
Discussion
TM is a chondroitin-sulfate proteoglycan present at the surface
of endothelial cells [4]. First discovered in rabbits [1, 21, it was
later purified from human placenta [31J. TM has been found on
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Fig. 5. TM mRNA expression in MC. Bright field micrographs of in situ hybridization using 35S-labeled RNA probes with methyl green nuclear
counterstaining. Numerous TM transcripts hybridized with the anti-sense probe were present in MC in situ in freshly isolated glomeruli (A). Similar
results were obtained with cultured MC (B). Controls (C-F). No specific hybridization either to freshly prepared (C) or cultured (D) MC with the sense
probe. When hybridized using the anti-sense probe, TM mRNA were strongly expressed in HUVEC (positive control cell; E), while no silver grains were
observed in human skin fibrohiasts (negative control cell; F) (X1000).
cultured ones, did not express detectable amounts of smooth
muscle a-actin. This finding is in agreement with previous obser-
currently identified in humans: the membrane integral protein vations concerning rat MC [25] and human normal kidney where
and a degraded form which is present in plasma [33].
The present study demonstrated that TM is expressed by native,
freshly prepared MC and by MC in primary culture both charac-
terized by a panel of specific positive and negative markers. MC
were not contaminated by other glomerular cells (neither endo-
thelial cells nor podocytes). Freshly prepared MC, in contrast to
a-aetin is strongly expressed only in glomerular hilar arterioles
[24]. When present, -actin mesangial expression was described as
focal and sparse but was greatly enhanced in diseased kidneys
[24].
On freshly isolated MC, labeling of the TM antigen gave an
intense granular pattern. A strong immunocytochemical reaction
all vascular endothelia (veins, arteries and capillaries), lymph
ducts and placental vessels [31, 32]. Two forms of TM are
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also occurred on MC in primary culture. The presence of TM in
cultured MC was confirmed by measurement of total TM antigen.
Moreover, TM was active on the surface of both MC preparations.
In spite of the possible degradation of some mRNA during the
sievings and collagenase treatments, in situ hybridization analysis
showed numerous TM mRNA transcripts, homogeneously distrib-
uted in MC freshly prepared from human kidney. This finding
demonstrated that TM was synthesized in vivo by MC and was not
picked up from the surrounding medium by MC.
With regard to the role of TM in MC, it could be similar to the
one that it plays in endothelial cells, that is, that of a powerful
anticoagulant. In vivo, MC are in close contact with blood through
capillary fenestrations and with plasma filtrate through the inter!
intramesangial channels [34]. By analogy with all the cells lining
body-fluid cavities, such as arachnoid membrane, pleural or
peritoneal mesothelia [35, 36], synovial tissue [37] or syncytiotro-
phoblast [32], MC might produce TM in an attempt to prevent
local fibrin formation, Because of the particular position of MC
between two different fluids [341, TM expression might be polar-
ized on MC membranes. This possibility should be investigated in
future studies.
In physiological states, TM expression, as visualized by immu-
nostaining, appears to be weak and localized at the vascular pole
[38]. In renal disorders, TM expression varies according to the
disease and the variations are difficult to match to the factors
known to be involved in TM regulation. The situation appears to
be even more complicated, since we found that TM is synthesized
in MC as well as in endothelial cells and possibly regulated in
these cells by different mechanisms. Increased TM expression was
observed in endothelial areas in biopsies of idiopathic or lupus-
related proliferative glomerulonephritis [38, 39], in contrast to a
steady state seen in non-proliferative glomerular diseases despite
the presence of microangiopathy [39]. Perhaps this overexpression
of TM represents an attempt to counteract the effects of proco-
agulant proteins and the promitogenic effects of thrombin [8, 14]
or other proinflammatory substances [18], but the true cause of
this increase remains unknown. TM was also shown to be over-
expressed during the repair phase of focal and segmental ne-
phropathy [40], suggesting that it takes part in the recovery
processes of endothelial and!or mesangial cells. Decreased intra-
graft TM expression [41] was described during human allograft
rejection [42] associated with the production of tumor necrosis
factor, which is known to inhibit TM synthesis in vitro in endo-
thelial cells [5] and in isolated glomeruli [18]. However, prolifer-
ative glomerulopathies are also known to be associated with a
dramatic increase in proinfiammatory cytokines, but there, sur-
prisingly, TM expression is not decreased hut increased [38, 39].
Therefore, in these cases a specific stimulus for TM production in
glomerular mesangial and!or endothelial cells might exist, even
more so because TM expression did not change in a septic rat
model of glomerular thrombotic microangiopathy [43]. It remains
to be determined which cell is involved in the different (graft
rejection and idiopathic or lupus-type) proliferative glomerulopa-
thies with inflammatory cytokines, in order to understand the
opposing situations observed in glomerular TM expression.
In conclusion, knowing that TM is expressed by two different
cell types in renal glomeruli should prompt further investigations
at the cellular level and shed more light upon the complex
mechanisms involved in glomerular pathology.
Acknowledgments
This work was supported by INSERM and by a grant from the
Association pour l'Utilisation du Rein Artificiel, Paris, France. We
gratefully acknowledge the Urology Department staff and Prof. Le Duc,
Hbpital Saint-Louis (Paris) for providing kidney samples; and Prof.
Ronco, Hôpital Tenon (Paris) and Dr. J. Amiral, Serbia (Asnières) for
kindly donating anti-podocalyxin antibody and TM kits, respectively.
Reprint requests to Dr. Marie-Claire Boffa, INSERM Unite 353, Hôpital
Saint-Louis, 1, avenue Claude J/ellefau.x, 75010 Paris, France.
References
1. OWEN WG, ESMON CT: Functional properties of an endothelial cell
cofactor for thrombin-catalyzed activation of protein C. J Biol Chem
256:5532—5535, 1981
2. ESMON NL, OWEN WG, ESMON CT: Isolation of a membrane-bound
cofactor for thrombin-catalyzed activation of protein C. J Biol Chem
257:859—864, 1982
3. ESMON CT: Thrombomodulin as a model of molecular mechanisms
that modulate protease specificity and function at the vessel surface.
FASEB J 9:946—955, 1995
4. Bouars MC, LUNDGREN-AKERLUND E, LINDAHL U: Isolation and
characterization of the glycosaminoglycan component of rabbit
thrombomodulin proteoglycan. J Biol Chem 265:15424—15431, 1990
5. DITrMAN WA, MAJERUS PW: Structure and function of thrombo-
modulin: A natural anticoagulant. Blood 75:329—336, 1990
6. ESMON CT, ESMON NL, HARRIS KW: Complex formation between
thrombin and thrombomodulin inhibits both thrombin-catalyzed fi-
brin formation and factor V activation. J Biol Chem 257:7944—7794,
1982
7. ESMON NL, CAROLL RC, ESMON CT: Thrombomodulin blocks the
ability of thrombin to activate platelets.JBiolChem 258:12238—12242,
1983
8. BOURIN MC: Effect of rabbit thrombomodulin on thrombin inhibition
by antithrombin in the presence of heparin. Thromb Res 54:27-39,
1989
9. WOLTHUIS A, BoEs A, RODEMANN HP, GROND J: Vasoactive agents
affect growth and protein synthesis of cultured mesangial cells. Kidney
mt 41:121—131, 1992
10. MENE P, CINOTrI GA, PUGLIESE F: Signal transduction in mesangial
cells. JAm Soc Nephrol 2(Suppl 2):S100—S106, 1992
11. SINGHAL PC, SCHARSCHMIDT LA, GIBBONS N, HAYS RM: Contraction
and relaxation of cultured mesangial cells on a silicone rubber surface.
Kidney mt 30:862—873, 1986
12. GLASS WF, RAMPT E, GARONI JA, FENTON JW, KREISBERG J1
Regulation of mesangial cell adhesion and shape by thrombin. Am J
Physiol 261:F336—F344, 1991
13. VILLAMEDIANA LM, RONDEAU E, HE CJ, MEDCALF RL, PERALDI MN,
LACAVE R, DELARUE F, SRAER JD: Thrombin regulates components
of the fibrinolytic system in human mesangial cells. Kidney mt
38:956—961, 1990
14. SCHREINER OF: The mesangial phagocyte and its regulation of
contractile cell biology. JAm Soc Nephrol 2(Suppl 2):S74—S82, 1992
15. ROBERTS AB, MACCUNE BK, SPORN MB: TGF-beta: Regulation of
extracellular matrix. Kidney Tnt 41:557—559, 1992
16. ABBOUD HE: Platelet-derived growth factor and mesangial cells.
Kidney In! 41:581—583, 1992
17. WANG A, TEMPLETON DM: Inhibition of mitogenesis and c-fos
induction in mesangial cells by heparan sulfates. Kidney mt 49:437—
448, 1996
18. HE CJ, KANFER A: Quantification and modulation of thrombomodu-
lin activity in isolated rat and human glomeruli. Kidney mt 41:1170—
1174, 1992
19. STRIKER GE, STRIKER U: Glomerular cell culture. Lab Invest 52: 121—
131, 1985
20. JAFFE EA, HOYER WL, NACHMAN RL: Synthesis of anti-hemophilic
factor antigen by cultured human endothelial cells. J Clin Invest
52:2757—2764, 1973
21. BAYREUTHER K, RODEMANN HP, HOMMEL R, DITTMANN K, ALBIEz
M, FRANCZ P1: Human skin fibroblasts in vitro differentiate along a
terminal cell lineage. Proc NatlAcad Sci USA 85:5112—5116, 1988
Pruna et al: Thrombomodulin in mesangial cells 693
22. TAKEUCHI A, YOSHIZAWA N, YAMAMOTO M, SAWASAKI Y, ODA T,
SEN00 A, NIwA H, FUSE Y: Basic fibroblast growth factor promotes
proliferation of rat glomerular visceral epithelial cells in vitro. Am J
Pathol 141:107—116, 1992
23. SCHNABEL E, DEKAN G, MIETTINEN A, FARQUHAR MG: Biogenesis of
podocalyxin, the major sialoglycoprotein, in the newborn rat kidney.
EurJ Cell Biol 48:313—326, 1989
24. ALPER5 CE, HUDKINS KL, GOWN AM, JOHNSON RJ: Enhanced
expression of "muscle-specific" actin in glomerulonephritis. Kidney mt
41:1134—1142, 1992
25. ELGER M, DRENCKHAHN D, NOBILING R, MUNDEL P, Kmz W:
Cultured rat mesangial cells contain smooth muscle alpha-actin not
found in vivo. Am J Pathol 42:497—509, 1993
26. HEYDERMAN E: Immunoperoxidase technique in histopathology: Ap-
plications, methods and controls. J Clin Pathol 32:971—978, 1979
27. Hsu SM, RAINE L, FANnER H: Use of avidin-biotin peroxidase
complex (ABC) in immunoperoxidase techniques: A comparison
between ABC and unlabelled antibody (PAP) procedures. J Histo-
chem Cytochem 29:577—580, 1981
28. AMIRAL J, ADAM M, MIMILLA F, LARRIVAZ 1, CHAMBRETTE B, BOFFA
MC: Design and variation of a new immunoassay for soluble forms of
thrombomodulin and studies on plasma. Hybridoma 13:205—213, 1994
29. ARCHIPOFF G, BERETZ A, FREYSSINET JM, KLEIN-SOYER C, BRISSON
C, CAZENAVE JP: Heterogeneous regulation of constitutive thrombo-
modulin or inducible tissue-factor activities on the surface of human
saphenous endothelial cells in culture following stimulation by inter-
leukin-1, tumour necrosis factor, thrombin or phorbol ester. Biochem
J 273:679—684, 1991
30. HOFLER H, CHILDERS H, MONTMINY MR, LECHAN RM, GOODMAN
RH, WOLFE HJ: In situ hybridization methods for the detection of
somatostatin mRNA in tissue sections using antisense RNA probes.
Histochem J 18:2—8, 1986
31. SALEM HH, MARUYAMA t, ISHII H, MAJERUS PW: Isolation and
characterization of thrombomodulin from human placenta. J Biol
Chem 259:12246—12251, 1984
32. MARUYAMA I, BELL CE, MAJERUS PW: Thrombomodulin is found on
endothelium of arteries, veins and lymphatics and on syncytiotropho-
blasts of human placenta. J Cell Biol 101:363—367, 1985
33. Is-nt H, MAJERUS PW: Thrombomodulin is present in human plasma
and urine. J Clin Invest 76:2178—2218, 1985
34. LATTA H: An approach to the structure and function of the glomerular
mesangium. JAm Soc Nephrol 2(Suppl 2):S65—S73, 1992
35. BOFFA MC, BURKE B, HAUDENSCHILD CC: Preservation of thrombo-
modulin antigen on vascular and extravascular surfaces. J Histochem
Cytochem 35:1267—1276, 1987
36. BOFFA MC, JACKMAN RW, PEYRI N, BOFFA JF, GEORGE B: Throm-
bomodulin in the central nervous system. Nouv Rev Fr Hématol
33:423—429, 1991
37. MAC CACHREN SS, DIGGS J, WEINBERG JB, DITITMAN WA: Thrombo-
modulin expression by human blood monocytes and by human
synovial tissue lining macrophages. Blood 78:3128—3132, 1991
38. MIZUTANI M, YUZAWA Y, MARUYAMA I, SAKAMOTO N, MATSUO 5:
Glomerular localization of thrombomodulin in human glomerulone-
phritis. Lab Invest 69:193—202, 1993
39. TOMURA 5, DEGUCHI F, MARUMO F, A0KI N: Enhanced presence of
thrombomodulin in the glomeruli of lupus glomerulonephritis. Clin
Nephrol 41:205—210, 1994
40. SHIIKI H, ENOMOTO Y, UYAMA H, NI5HIN0 T, HoRn Y, IwANo M,
DOW K: Distribution of thrombomodulin in patients with focal and
segmental glomerulosclerosis (FSGS). Nippon Jinzo Gakkai Shi 36:
890—895, 1994
41. T5ucHIDA A, SALEM H, THOMSON N, HANCOCK WW: Tumor necrosis
factor production during human allograft rejection is associated with
depression of plasma protein C and free protein S levels and
decreased intragraft thrombomodulin expression. J Exp Med 175:81—-
90, 1992
42, HABIB R, ZUROWSKA A, HINGLAIS N, GUBLER MF, ANTIGNAC C,
NIAUDET P, BROYER M, GAGNADOUX MF: A specific glomerular
lesion of the graft: Allograft glomerulopathy. Kidney mt 44(Suppl
42):S104—S111, 1993
43. LA5zIK Z, CARSON CW, NADASDY T, JOHNSON LD, LERNER MR,
BRACKEYr DJ, ESMON CT, SILVA FG: Lack of suppressed renal
thrombomodulin expression in a septic rat model with glomerular
thrombotic microangiopathy. Lab Invest 70:862—867, 1994
